British Columbia's Health Minister, Adrian Dix, expressed concern over the potential impact of a decision by the U.S. Food and Drug Administration (FDA) to permit Florida to import prescription drugs from Canada. In an interview on Rosemary Barton Live, Dix labeled the FDA's approval of Florida's request to purchase Canadian drugs as a significant threat, describing it as an "effective raid on Canada's drug supply."
The FDA's move is part of an effort by Florida to save up to $150 million annually, but pharmaceutical companies on both sides of the border oppose the decision. Joelle Walker, Vice President of Public Affairs at the Canadian Pharmacists Association, expressed skepticism about the feasibility of drug imports from Canada, citing historical drug shortages in Canada.
This is not the first time the U.S. has considered diverting drugs from Canada. In 2019, then-President Donald Trump supported a plan for bulk drug imports, prompting Canada to take measures to prevent exports.
Dix highlighted the potential consequences of allowing drug imports, emphasizing the risk of causing drug shortages in Canada. However, he expressed doubt about the proposal's viability, citing the federal government's powers and pharmaceutical companies' opposition as reasons it may not proceed.
While acknowledging the reassuring language in existing regulations prohibiting sales outside Canada that could cause or worsen drug shortages, Dix emphasized the need for the federal government to take action to protect the Canadian drug supply. Federal Health Minister Mark Holland assured that the government would take necessary measures to prevent shortages.
Dix drew attention to British Columbia's previous action in addressing the export of the diabetes medication Ozempic, highlighting the need for robust regulations to safeguard the drug supply, especially in the face of proposals that could impact it on a significant scale.